Small business labeling guidance
This article was originally published in The Tan Sheet
Executive Summary
Draft guidance titled "1Labeling OTC Human Drug Products (Small Entity Compliance)", published in the Federal Register Dec. 9, is an effort "to help small businesses better understand the new over-the-counter labeling requirements and to prepare new labeling within the prescribed implementation compliance dates," FDA says. This is the third guidance the agency has issued on "Drug Facts" labeling, following one on ANDA labeling and another on column formats (2"The Tan Sheet" Oct. 21, 2002, p. 5). The draft "describes how to list those inactive ingredients that are different when a finished OTC drug product is obtained from multiple suppliers," the agency notes...
You may also be interested in...
Final label guidance issued
FDA finalizes its small entity compliance guide for Labeling OTC Human Drug Products originally published in December 2004 (1"The Tan Sheet" Dec. 13, 2004, In Brief). In a May 13 Federal Register notice, the agency says it made only technical and minor editorial changes in its final 2guidance, which discusses standardized content and format requirements for OTC drugs and drug-cosmetics
FDA OTC Labeling Guidance Allows Flexible Approach To Template Use
OTC drug manufacturers that choose to employ FDA's "Drug Facts" labeling templates do not have to follow them verbatim, the agency says in a guidance published in the Oct. 18 Federal Register
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.